CHINA RESOURCES PHARMACEUTICAL GROUP LIMITED

China Resources Pharmaceutical Group Limited

3320

HK0000311099

Pharmaceuticals

Delayed Hong Kong S.E. Other stock markets 11:15:21 2024-04-18 pm EDT			5-day change	1st Jan Change
4.7 ^HKD	+0.21%		-0.63%	-8.38%

Apr. 18	China Resources Pharma Unit Issues 3 Billion Yuan Bonds	MT
Apr. 12	China Resources Dong-E-E-Jiao Company Limited Provides Earnings Guidance for the Three Months Ended 31 March 2024	CI

China Resources Pharmaceutical Group Limited Declares Final Dividend for the Year Ended 31 December 2021

May 27, 2022 at 07:39 am EDT

China Resources Pharmaceutical Group Limited at the Annual General Meeting held on 27 May 2022 declared a final dividend of HKD 0.15 per share for the year ended 31 December 2021.

Latest news about China Resources Pharmaceutical Group Limited

China Resources Pharma Unit Issues 3 Billion Yuan Bonds	Apr. 18	MT
China Resources Dong-E-E-Jiao Company Limited Provides Earnings Guidance for the Three Months Ended 31 March 2024	Apr. 11	CI
China Resources Pharmaceutical Posts Gains in Full Year 2023 Profit	Mar. 26	MT
China Resources Pharmaceutical Group Limited Proposes Final Dividend for the Year Ended 31 December 2023, Payable on 19 July 2024	Mar. 26	CI
China Resources Pharmaceutical Group Limited Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 26	CI
CR Boya Bio-Pharmaceutical's 2023 Profit Falls on Lower Revenue	Mar. 14	MT
Nomura Adjusts CR Pharmaceutical Group’s Price Target to HK$8.80 From HK$9.08, Keeps at Buy	Mar. 11	MT
CR Sanjiu Expects Increase in 2023 Profit	Jan. 24	MT
China Resources Pharmaceutical Unit Completes Capital Increase; Shares Fall 3%	Jan. 08	MT
China Resources Pharmaceutical Unit Enters Share Subscription Deals to Boost Capital	Dec. 28	MT
China Resources Pharmaceutical Group Limited Announces Management Changes, Effective on 27 December 2023	Dec. 27	CI
China Resources Pharma Unit Boosts Stake in Jiangzhong Pharma Parent	Dec. 27	MT
China Resources Pharmaceutical Subsidiary Begins Bidding for Potential Share Issuance	Nov. 27	MT
China Resources Pharmaceutical Group Subsidiary Records Rise in Nine-Month Attributable Profit	Nov. 01	MT
Dong-E-E-Jiao's Nine-Moth Profit Rises on Higher Revenue	23-10-31	MT
CR Boya Bio-Pharmaceutical's January-September Profit Increases	23-10-25	MT
Dong-E-E-Jiao Expects January-September Attributable Profit to Rise Up to 60%	23-10-10	MT
China Resources Pharma's Profit Marginally Rises in H1	23-08-31	MT
China Resources Pharmaceutical Group Limited Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-31	CI
CR Sanjiu Medical & Pharmaceutical's H1 Attributable Profit Rises 31%	23-08-29	MT
KPC Pharmaceuticals' Attributable Profit Rises 3.1%; Shares Slip 4%	23-08-29	MT
China Resources Pharmaceutical's Subsidiaries Log Increases in H1 Profits	23-08-25	MT
China Resources Boya's H1 Attributable Profit Jumps 16.9%	23-08-22	MT
Dong-E-E-Jiao's H1 Attributable Profit Surges 72%	23-08-06	MT
Nomura Adjusts China Resources Pharmaceutical Group's Price Target to HK$9.08 From HK$9.32, Keeps at Buy	23-07-27	MT

Chart China Resources Pharmaceutical Group Limited

Duration

Period

Chart China Resources Pharmaceutical Group Limited

More charts

CHINA RESOURCES PHARMACEUTICAL GROUP LIMITED is a Hongkong-based investment holding company. The Company, along with its subsidiaries, is principally engaged in the research and development, manufacturing, distribution and retail of pharmaceutical and other healthcare products. The Company mainly operates through three segments. Pharmaceutical Manufacturing segment is engaged in the research and development, manufacturing and sale of pharmaceutical and other healthcare products. Pharmaceutical Distribution segment is engaged in the provision of distribution solutions to pharmaceutical manufacturers and dispensers, such as hospitals and other medical institutions, distributors and retail pharmacies. Pharmaceutical Retail segment is involved in the operation of retail pharmacies in China and Hongkong.

Sector

Pharmaceuticals

Calendar

2024-08-21 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for China Resources Pharmaceutical Group Limited

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

4.69 HKD

Average target price

7.406 HKD

Spread / Average Target

+57.90%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
CHINA RESOURCES PHARMACEUTICAL GROUP LIMITED	-8.38%	3.82B
ELI LILLY AND COMPANY	+27.97%	676B
NOVO NORDISK A/S	+23.58%	554B
JOHNSON & JOHNSON	-7.02%	349B
MERCK & CO., INC.	+14.85%	318B
ABBVIE INC.	+6.25%	291B
ASTRAZENECA PLC	+2.96%	210B
NOVARTIS AG	-0.41%	204B
ROCHE HOLDING AG	-10.02%	194B
PFIZER, INC.	-11.81%	144B

Other Pharmaceuticals